A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma.
Morris
J C
JC
Ramsey
W J
WJ
Wildner
O
O
Muslow
H A
HA
Aguilar-Cordova
E
E
Blaese
R M
RM
D000256:Adenoviridae / Q000235:genetics*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D015316:Genetic Therapy; D005822:Genetic Vectors; D018259:Herpesvirus 1, Human / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*; D013937:Thymidine Kinase / Q000235:genetics*
D000998:Antiviral Agents; D013937:Thymidine Kinase; D015774:Ganciclovir